Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: Comparison between interferon-α-2a and interferon-α-2b

Clinical Drug Investigation

Volumn 26, Issue 11, 2006, Pages 655-662

  Neri, Sergio ^a,b   Pulvirenti, Davide ^a   Bertino, Gaetano ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Policlinico di Catania   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; BENZODIAZEPINE; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; THYROID ANTIBODY; VENLAFAXINE;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ANAPHYLACTOID PURPURA; ANOREXIA; ANTIBODY BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; DELIRIUM; DEMOGRAPHY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; EMOTIONAL DISORDER; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HAMILTON SCALE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; HYPOTHYROIDISM; INCIDENCE; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; LICHEN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MYALGIA; NAUSEA; NEUTROPHIL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSYCHOSIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SJOEGREN SYNDROME; SKIN DISEASE; STRUCTURED INTERVIEW; THROMBOCYTE;

ADULT; ANTIVIRAL AGENTS; DEPRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PATIENT COMPLIANCE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 33750342122     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626110-00005     Document Type: Article

References (23)

1. Foster GR. Pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004; 20: 825-30
2. First Annual meeting of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 2006; 1: S56-9
3. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol 1996; 24: 38-47
4. Scalori A, Pozzi M, Bellia V, et al. Interferon-induced depression: prevalence and management. Dig Liver Dis 2005; 37: 102-7
5. Bonaccorso S, Marino V, Biondi M, et al. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 2002; 72: 237-41
6. Dieperink E, Ho SB, Tetrick L, et al. Suicidal ideation during interferon-alpha 2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psych 2004; 26: 237-40
7. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 4315
8. DSM IV-TR: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Arlington (VA): American Psychiatric Association, 2000
9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
10. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965; 12: 63-70
11. Steinberg M. Structured Clinical Interview for DSM-IV axis disorders. Arlington (VA): American Psychiatric Association, 1994
12. Malaguarnera M, Di Fazio I, Restuccia S, et al. Interferon alpha induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychology 1998; 37: 93-7
13. Diepering E, Willebring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157: 867-76
14. Madday WC. Safety of combination interferon alpha-2b/ribavirin therapy on chronic hepatitis C-relapsed and treatment-naïve patients. Semin Liver Dis 1999; 19 Suppl. 1: 67-75
15. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999; 461: 25-46
16. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004; 82: 175-90
17. Juengling FD, Ebert D, Gut O, et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl) 2000; 152: 383-9
18. Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 2002; 347: 975-82
19. Manns MP, McHutchison JG, Gordon SC, et al. Pegintron alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65
20. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Pegintron alpha 2-a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 436-55
21. Zeuzem S, Diago M, Gane E, et al. Peginterferon alpha-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724- 32
22. Kraus MR, Schafer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alpha-2b therapy. Psychiatry 2003; 64: 708-14
23. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C. Hepatology 2002; 36 Suppl. 5: S1-2